Develops drugs for infectious diseases and cancer.
Jun 2026Revenue $303M/yrExpenses $583M/yr
No trendCash runway ≈ 2.6 years from Jun 2026
Figures by year
When will Vir Biotechnology be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $303M and expenses $583M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $68.6M | $548M | −$479M |
| Dec 2024 | $74.2M | $661M | −$587M |
| Dec 2023 | $86.2M | $770M | −$684M |
| Dec 2022 | $1.62B | $783M | $833M |
| Dec 2021 | $1.10B | $675M | $421M |
| Dec 2020 | $76.4M | $373M | −$297M |
| Dec 2019 | $8.09M | $186M | −$178M |
| Dec 2018 | $10.7M | $129M | −$119M |
| Dec 2017 | $2.71M | $84.2M | −$81.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.